- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | NewcelX To Acquire Mazindol Assets From REA Holdings | 5 | RTTNews | ||
| Mi | NewcelX Ltd.: NewcelX Enters into Binding Term Sheet to Divest Legacy Mazindol Portfolio (CVR), Providing for Upfront Cash, Equity Ownership and Up to $55 Million in Potential Milestone Payments | 5 | GlobeNewswire (USA) | ||
| Mi | NewcelX Ltd. - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
| NEWCELX Aktie jetzt für 0€ handeln | |||||
| 28.09. | NewcelX Ltd.: NewCelX Management to Attend Breakthrough T1D Congress in Philadelphia, Advancing Its Mission to Develop a Cure for Type 1 Diabetes | 1 | GlobeNewswire (USA) | ||
| 18.09. | NLS Pharmaceutics GAAP EPS of -$0.96 | 1 | Seeking Alpha | ||
| 18.09. | NewcelX Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 31.07. | NewcelX Ltd. - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
| 31.07. | NewcelX Ltd.: NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing | 1 | GlobeNewswire (USA) | ||
| 15.07. | NewcelX Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 13.07. | Laidlaw initiates NewcelX stock with buy rating on diabetes therapy | 1 | Investing.com | ||
| 08.07. | NewcelX beruft Diabetes-Forscher Ricordi in den wissenschaftlichen Beirat | 1 | Investing.com Deutsch | ||
| 08.07. | NewcelX appoints diabetes researcher Ricordi to advisory board | 1 | Investing.com | ||
| 08.07. | NewcelX Ltd.: NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board | 2 | GlobeNewswire (USA) | ||
| 08.07. | NewcelX Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 01.07. | NewcelX Ltd.: NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes | 555 | GlobeNewswire (Europe) | ZURICH, July 01, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. ("NewcelX"; Nasdaq: NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, announced the successful completion... ► Artikel lesen | |
| 30.06. | NewcelX Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 15.06. | NewcelX Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 05.06. | NewcelX Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 27.05. | NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes | 801 | GlobeNewswire (Europe) | Pre-IND meeting has been scheduled with FDA to advance type 1 diabetes treatment to First-In-Human clinical trial ZURICH, Switzerland, May 27, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. ("NewcelX"; Nasdaq:... ► Artikel lesen | |
| 27.05. | NewcelX Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOFRONTERA | 3,110 | +6,51 % | Biofrontera: Halbjahreszahlen da - was jetzt wichtig ist | ||
| DEFENCE THERAPEUTICS | 0,225 | -0,88 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Convertible Debenture Interest Payment | Montreal, Quebec--(Newsfile Corp. - October 23, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing... ► Artikel lesen | |
| TRAWS PHARMA | 0,240 | -11,11 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -4- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS1509643029 CENNTRO... ► Artikel lesen | |
| CURIS | 0,747 | -26,11 % | Morning Market Movers: Curis, Inc., Darkiris, Amdocs, Nurix Therapeutics See Big Swings | NICOSIA (dpa-AFX) - At 8:05 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| GENPREX | 2,070 | -3,27 % | Genprex, Inc. - 8-K, Current Report | ||
| TVARDI THERAPEUTICS | 0,735 | -3,92 % | Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update | Reported topline healthy volunteer results for next-generation STAT3 inhibitor TTI-109, confirming the prodrug design, improved tolerability and reductions in disease-relevant immune cell populations... ► Artikel lesen | |
| NEOVACS | 0,002 | -89,74 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 22.10.2026 | Das Instrument 1DD FR001400H2X4 TONNER DRON. S.A.EO-,0001 EQUITY wird ex Kapitalmassnahme gehandelt am 22.10.2026 The instrument 1DD FR001400H2X4 TONNER DRON. S.A.EO-,0001 EQUITY is traded ex capital... ► Artikel lesen | |
| ALAUNOS THERAPEUTICS | 1,770 | -2,75 % | Paragon Labs Adds Former Apogee Leaders As Alaunos Completes Velaris Acquisition; Stock Up | WASHINGTON (dpa-AFX) - Paragon Labs announced that several former senior executives from Apogee Therapeutics (APGE) have joined its leadership team, while Alaunos Therapeutics, Inc. (TCRT) completed... ► Artikel lesen | |
| MARKER THERAPEUTICS | 0,870 | +1,16 % | Marker Therapeutics sichert sich FDA-Förderung über 2,6 Millionen US-Dollar für Krebsstudie | ||
| AINOS | 0,630 | -13,73 % | Ainos, Inc.: Ainos Surpasses 3 Billion Real-World Chemical Data Points, Advancing Chemical Intelligence for Smart Factories | Chemical dataset surpasses 3 billion data points, more than tripling September milestoneFollowing delivery of 1,400 AI Nose systems, continued collaboration with a major semiconductor assembly and test... ► Artikel lesen | |
| MATINAS BIOPHARMA | 1,260 | +6,33 % | Matinas BioPharma Holdings, Inc. - 8-K, Current Report | ||
| ENVERIC BIOSCIENCES | 1,390 | -4,79 % | Enveric Biosciences Reports Favorable Brain Activity Data for Lead Psychiatric Drug Candidate | ||
| NEUPHORIA THERAPEUTICS | 2,820 | -5,69 % | Neuphoria Therapeutics, Inc.: Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc | Neuphoria Therapeutics confirms it is in talks with Scancell Holdings plc about a possible combination BURLINGTON, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. ("Neuphoria"... ► Artikel lesen | |
| SCINAI IMMUNOTHERAPEUTICS LTD | 0,440 | -1,96 % | Scinai Immunotherapeutics Ltd.: Scinai Reports Significant Revenue Growth in First Nine Months of 2026 as CDMO Business Expands | October agreement advances the U.S. customer program to approximately $5.1 million in committed base services JERUSALEM, Nov. 5, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai"... ► Artikel lesen | |
| CLEARMIND MEDICINE | 5,993 | 0,00 % | Clearmind Medicine Inc.: Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder | Published patent application covers 3-MMC-based treatment of dyskinesia, including in combination with Palmitoylethanolamide (PEA) Vancouver, Canada, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine... ► Artikel lesen |
NEWCELX LTD gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 2,740 Euro und damit +8,30 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEWCELX LTD finden Sie auf Wallstreet Online.